the-wiseguy.com
Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214.
Maybe I’m a little late. But in december Nektar announced the following: Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating…